Lakeland, Fla. — Molecular staging of melanoma can identify patients with missed micrometastatic disease, offering them the chance to receive more aggressive treatment, thus offering them the best chance of survival.
Addressing Disparities in Skin-Aging Prevention Among Women of Color
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment
Upadacitinib Outperforms Dupilumab in Primary and Secondary End Points in Head-to-Head AD Study
ReV Up Your Vitiligo Treatment Strategies
Seemal Desai, MD, Responds to Study Suggesting Melanoma is Overdiagnosed in White Patients
Federal Trade Commission Votes to Ban Noncompete Clauses Between Employers and Workers